Expressive

rs115175234 - SH2B2

Magnitude 4.5 · 1 study on file

Reported associations

  • Genome-wide association study of type 2 diabetes in Africa - Unknown journal (n.d.) · Unknown authors · PubMed 31049640

    ABSTRACT: Aims/hypothesis Genome-wide association studies (GWAS) for type 2 diabetes have uncovered >400 risk loci, primarily in populations of European and Asian ancestry. Here, we aimed to discover additional type 2 diabetes risk loci (including African-specific variants) and fine-map association signals by performing genetic analysis in African populations. Methods We conducted two type 2 diabetes genome-wide association studies in 4347 Africans from South Africa, Nigeria, Ghana and Kenya and meta-analysed both studies together. Likely causal variants were identified using fine-mapping approaches. Results The most significantly associated variants mapped to the widely replicated type 2 diabetes risk locus near TCF7L2 (p = 5.3 × 10−13). Fine-mapping of the TCF7L2 locus suggest

Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.

Lifestyle context

Concrete actions anchored to the cited research. We do not prescribe, we describe.

Diet

  • Prioritize low glycemic index carbohydrates Moderate

    Low glycemic index foods reduce insulin demand and glucose spikes, beneficial for T2D risk reduction.

    Replace refined grains with whole grains; limit added sugars

Discuss with your doctor

  • Discuss Type 2 diabetes genetic risk Moderate

    Elevated genetic risk for T2D warrants clinical assessment to determine screening frequency and intervention intensity.

Exercise

  • Regular aerobic exercise Moderate

    Physical activity improves insulin sensitivity and glucose metabolism, reducing Type 2 diabetes risk.

    150 minutes moderate-intensity aerobic exercise weekly

Screening

  • Periodic fasting glucose and HbA1c testing Moderate

    SH2B2 G allele carriers have 1.64-fold increased Type 2 diabetes risk; screening enables early detection.

    Fasting glucose and HbA1c every 1-2 years, or per healthcare provider guidelines